Abstract

The ultimate objective of this program is the cure of children with cancer. The program is a coordinated effort of therapy and study which includes therapeutic trials, studies of tumor cell biology, and studies of the effects of therapy on normal tissues. The program consists of a core section and four projects. The core section provides for resource personnel, patient data base, biostatistics, and two resource laboratory functions - a tissue culture and cytogenetics laboratory and an animal xenograft developmental laboratory. The projects are: (1) neuroblastoma therapy and cell biology; (2) rhabdomyosarcoma: a laboratory model for pharmacological studies; (3) Ewing's sarcoma therapy and cell kinetics as well as features of biological behavior; (4) phase I and II trials of new agents for refractory tumors. All projects have the same ultimate objective through a variety of disciplines and approaches. The organizational structure provides the means for unified and coordinated effort.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA023099-07
Application #
3093027
Study Section
Cancer Therapeutics Program Project Review Committee (CTR)
Project Start
1978-08-01
Project End
1988-01-31
Budget Start
1985-02-01
Budget End
1986-01-31
Support Year
7
Fiscal Year
1985
Total Cost
Indirect Cost

  Institution

Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105

  Publications

Dowless, Michele; Lowery, Caitlin D; Shackleford, Terry et al. (2018) Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling. Clin Cancer Res 24:6028-6039
Bishop, Michael W; Advani, Shailesh M; Villarroel, Milena et al. (2018) Health-Related Quality of Life and Survival Outcomes of Pediatric Patients With Nonmetastatic Osteosarcoma Treated in Countries With Different Resources. J Glob Oncol :1-11
Wang, Tingting; Liu, Lingling; Chen, Xuyong et al. (2018) MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent. Cell Death Dis 9:220
Feng, Helin; Tillman, Heather; Wu, Gang et al. (2018) Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines. Oncotarget 9:27087-27091
Hu, Dongli; Jablonowski, Carolyn; Cheng, Pei-Hsin et al. (2018) KDM5A Regulates a Translational Program that Controls p53 Protein Expression. iScience 9:84-100
Power-Hays, Alexandra; Friedrich, Paola; Fernandez, Gretchen et al. (2017) Delivery of radiation therapy in resource-limited settings: A pilot quality assessment study. Pediatr Blood Cancer 64:
Brennan, Rachel C; Qaddoumi, Ibrahim; Mao, Shenghua et al. (2017) Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma. J Clin Oncol 35:72-77
Yu, Peter Y; Gardner, Heather L; Roberts, Ryan et al. (2017) Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One 12:e0181885
Yang, Jun; Milasta, Sandra; Hu, Dongli et al. (2017) Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox. Cancer Res 77:4626-4638
Brennan, Rachel C; Qaddoumi, Ibrahim; Billups, Catherine A et al. (2016) Patients with retinoblastoma and chromosome 13q deletions have increased chemotherapy-related toxicities. Pediatr Blood Cancer 63:1954-8

Showing the most recent 10 out of 814 publications